Mitigating Blue-Light Risk in Display-Based Digital Therapeutics: A Practical Framework to Support Clinical Efficacy.
The review states that blue-rich display emission in the 450–480 nm band, particularly with evening exposure, can suppress melatonin via melanopsin-mediated ipRGC pathways and perturb circadian timing, potentially attenuating digital therapeutic efficacy. It …